Arellanes-García L, Padilla-Aguilar G, Navarro-Lópeza P, Espinoza-Martínez C

Language: Spanish
References: 17
Page: 363-366
PDF size: 60.04 Kb.

ABSTRACT

Purpose: To compare the efficacy and safety of prednisolone acetate 1% vs. rimexolone 1% ophthalmic suspension in the treatment of acute anterior uveitis (AAU) in HLA-B27+ patients.
Methods: Sixty–eight AAU HLA-B27+ patients were randomly selected for treatment with prednisolone acetate 1% or Rimexolone 1%. All patients showed mild to moderate anterior chamber inflammation. This was a prospective, randomized, double blind, clinical trial.
Results: There was no statistically significant difference between both groups when anterior chamber cells were measured. In the rimexolone group, flare diminished since the first week. In both groups the intraocular pressure (IOP) raised since the first week; the increase washighly significant in the rimexolone group. Final intraocular pressure was higher in the prednisolone group.
Conclusion: Rimexolone 1% is as effective as prednisolone acetate 1% in the treatment of mild to moderate AAU HLA-B27+. IOP increased in both groups, but this variation was not clinically significant.

REFERENCES

1. Friedlaender MH. Corticosteroid therapy of ocular inflammation. Int Ophthalmol, 1983:23,175-182.

2. Leopold IH, Gaster RN. Ocular inflammation and antiinflammatory drugs. En: The cornea. Kaufman HE, McDonald MB, Barron BA, Waltman SR (eds.) Churchill Livingstone, New York, 1988, pp 67-84.

3. Fingeret M, Potter JW, Bartlettt JD. Uveitis. En: Clinical Ocular Pharmacology. Bartlett JD, Jaanus SD. (Eds.) Butterworth Heineman. Boston 1989:623-638.

4. Foster CS, Alter G, DeBarge LR, Raizman MB, Crabb JL, Santos CI, et al. Efficacy and safety of Rimexolone 1% ophthalmic suspension vs. 1% prednisolone acetate in the treatment of uveitis. Am J Ophthalmol 1996;122:171-182.

5. Assil K, Massry G, Lehmann R, Fox K, Stewart R. Control of ocular inflammation after cataract extraction with rimexolone 1% ophthalmic suspension. J Cataract Refract Sur, 1997;23:750-757.

6. Rosenbaum JT. HLA B27 Associated Disease. En: Ocular Infection and Immunity. Pepose JS, Holland GN, Wilhelmus KR (Eds.). St. Louis, Mosby-Year Book, 1996:475-484.

7. Hogan MJ, Kimura SJ, Thygeson P. Signs and symptoms of uveitis:I. Anterior uveitis. Am J Ophthalmol 1959;47:155-170.

8. Kimura S. Sign and symptoms of uveitis: II. Classification of the posterior manifestations of uveitis. Am J Ophthalmol 1959; 47:171-176.

9. Zachary A A, Teresi GA. ASHÍ Laboratory Manual, Second Edition. American Society for Histocompatibility and Immunogenetics, Kansas City, 1990

10. Darrell RW, Kurland L, Wagenerti P. Epidemiology of uveitis: incidence and prevalence in a small community. Arch Ophthalmol 1962;68:502-514

11. Armaly MF. Effects of corticosteroid on intraocular pressure and fluid dynamics: 1. The effect of dexamethasone in the normal eye. Arch Ophthalmol 1963;70:482-491.

12. Mindel JS, Tavitian HO, Smith H Jr, Walker EC. Comparative ocular pressure elevation by medrysone, fluorometholone, and dexamethasone phosphate. Arch Ophthalmol 1980;98:1577-1578.

13. Frangie JP, Leibowitz HM. Steroids. Int Ophthalmol Clin 1993;33:9-29.

14. Mindel JS, Goldberg J, Tavitian HO. Similarity of the intraocular pressure response to different corticosteroids esters when compliance is controlled. Ophthalmol 1979;86:99-107.

15. Jaanus SD, Lesher GA. Anti–Inflammatory drugs. In: Clinical Ocular Pharmacology. Bartlett JD, Jaanus SD (Eds.) 3a ed. Butterworth-Heineman, Boston, 1995, pp 303-335.

16. Harper SL, Chorich LJ, Foster CS. Diagnosis of Uveitis. In: Diagnosis and Treatment of Uveitis. Foster CS y Vitale AT (Eds.) WB Saunders, Philadelphia, 2001,pp79-103.

17. Kulkarni PS. Steroids in Ocular Therapy. En: Textbook of Ocular Pharmacology. Zimmerman TJ, Karanjit SK, Mordechai S, et al. (Eds.) Lippincott-Raven Publishers, Philadelphia, 1997,pp61-74.